Lupin Ltd. sells U.S. Women's Health Specialty Business, including SOLOSEC, to Evofem Biosciences for up to $84M.

Pharma company Lupin Ltd. has divested its U.S. Commercial Women's Health Specialty Business to Evofem Biosciences, Inc., a U.S. biopharmaceutical company focused on women's health. The divestment focuses on commercializing SOLOSEC (secnidazole) 2g oral granules, an FDA-approved single-dose antimicrobial agent for treating bacterial vaginosis and trichomoniasis. Under the deal, Lupin may receive up to $84 million based on future contingent milestones.